{"id":239553,"date":"2026-06-24T19:08:56","date_gmt":"2026-06-25T00:08:56","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/single-dose-lsd-drug-successfully-treats-depression-in-key-human-trial"},"modified":"2026-06-24T19:08:56","modified_gmt":"2026-06-25T00:08:56","slug":"single-dose-lsd-drug-successfully-treats-depression-in-key-human-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/single-dose-lsd-drug-successfully-treats-depression-in-key-human-trial","title":{"rendered":"Single-dose LSD drug successfully treats depression in key human trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/single-dose-lsd-drug-successfully-treats-depression-in-key-human-trial.jpg\"><\/a><\/p>\n<p>Disclaimer: Do NOT attempt without proper medical supervision.<\/p>\n<p>In a paradigm-shifting breakthrough, Phase III clinical trials of DT120 \u2014 a novel, pharmaceutical-grade formulation of LSD \u2014 have demonstrated unprecedented efficacy in treating Major Depressive Disorder (MDD) following just a single dose. The study, encompassing 149 patients, revealed that a one-time administration of DT120 significantly outperformed a placebo, achieving the trial\u2019s primary endpoint by reducing MADRS depression scores by an 8-point margin at six weeks. Remarkably, patients experienced rapid therapeutic relief within just one week, showcasing a massive 14-point advantage over the placebo group. Unlike conventional daily antidepressants that often take weeks to manifest effects, DT120 delivers profound and sustained symptom reduction from a single intervention. Hailed by Definium Therapeutics\u2019 CEO Rob Burrow as a potential \u201cbest-in-class\u201d therapy, these groundbreaking findings not only pave the way for expedited regulatory approval but also underscore the transformative potential of psychedelics to fundamentally revolutionize modern mental health care.<\/p>\n<hr>\n<p>Definium Therapeutics has announced strong results in a phase 3 trial of its single-dosed lysergide (LSD) drug DT120 in treating adults with <a class=\"\" href=\"https:\/\/refractor.io\/tag\/depression\/\" data-cms-ai=\"0\">major depressive disorder<\/a> (MDD), meeting its primary goal and all key secondary efficacy endpoints in the first trial of its kind.<\/p>\n<p>The results come from the Emerge trial, a randomized, double-blind, placebo-controlled study featuring 149 participants aged 18 to 74 years enrolled across 20 sites. The participants all met specific MDD measures. They needed to have a DSM-5-confirmed diagnosis of MDD, a Montgomery-\u00c5sberg Depression Rating Scale (MADRS) score of at least 26 and a Clinical Global Impression\u2013Severity (CGI-S) score of at least 4 at screening and baseline.<\/p>\n<p>The study examined the effectiveness of a single 100 \u00b5g dose of DT120 ODT compared with a placebo in alleviating MDD symptoms. In 2023, we covered an earlier trial of lysergide, which had <a class=\"\" href=\"https:\/\/refractor.io\/psychedelics\/single-dose-drug-quash-anxiety-trial\/\" data-cms-ai=\"0\">shown positive results in treating general anxiety disorder<\/a> (GAD).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Disclaimer: Do NOT attempt without proper medical supervision. In a paradigm-shifting breakthrough, Phase III clinical trials of DT120 \u2014 a novel, pharmaceutical-grade formulation of LSD \u2014 have demonstrated unprecedented efficacy in treating Major Depressive Disorder (MDD) following just a single dose. The study, encompassing 149 patients, revealed that a one-time administration of DT120 significantly outperformed [\u2026]<\/p>\n","protected":false},"author":701,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-239553","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/701"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=239553"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239553\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=239553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=239553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=239553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}